RCAN2 and metabolic dysfunction-associated steatotic liver disease: Further analyses using ROC curves found that serum RCAN2 may be a candidate biomarker for the diagnosis of NAFLD (AUC 0.663, sensitivity 63.7%, and specificity 61.3%).